{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:18:23Z","timestamp":1697343503965},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T00:00:00Z","timestamp":1351555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Secondary hyperparathyroidism remains a serious problem in hemodialysis patients. The use of vitamin D analogs still constitutes a basis for its treatment. This study was carried out to evaluate the efficacy of intravenous administration of alfacalcidol once versus twice or thrice weekly in hemodialysis patients with secondary hyperparathyroidism. Twenty\u2010nine end\u2010stage renal disease patients maintained on hemodialysis for more than one year were included in this prospective study after signing the consent. These patients with secondary hyperparathyroidism had been on intravenous alfacalcidol twice or thrice per week and were followed up to 4\u2003months (stage 1). Then they were shifted to intravenous alfacalcidol once weekly starting with the last total weekly intravenous dose for another 4\u2003months (stage 2). The dose of alfacalcidol was adjusted according to intact parathyroid hormone, serum calcium and phosphorus levels, and calcium\u2010phosphorus product. Intact parathyroid hormone, calcium, phosphorus, calcium\u2010phosphorus product were measured monthly. Parathyroid ultrasound was done as a baseline and then repeated at the end of stage 1 and stage 2. The intact parathyroid hormone was reduced from 49.72\u2003\u00b1\u20032.72\u2003pmol\/L (mean\u2003\u00b1\u2003standard error of the mean [SEM] during stage 1 to 42.13\u2003\u00b1\u20032.15\u2003pmol\/L during stage 2 (<jats:italic>P<\/jats:italic>\u2003=\u20030.005). Dose of alfacalcidol was reduced from 18.80\u2003\u00b1\u20031.15\u2003\u00b5g\/month (mean\u2003\u00b1\u2003SEM) in stage 1 to 15.18\u2003\u00b1\u20031.27\u2003\u00b5g\/month in stage 2 (<jats:italic>P<\/jats:italic>\u2003=\u20030.008), and consequently the cost of alfacalcidol was reduced from 21.05\u2003\u00b1\u20031.25\u2003US$\/month (mean\u2003\u00b1\u2003SEM) during stage 1 to 16.87\u2003\u00b1\u20031.40 US$\/month during stage 2 (<jats:italic>P<\/jats:italic>\u2003=\u20030.008). Although the phosphorus level increased from 1.56\u2003\u00b1\u20030.36\u2003mmol\/L (mean\u2003\u00b1\u2003SD) in stage 1 to 1.70\u2003\u00b1\u20030.46\u2003mmol\/ L in stage 2 (<jats:italic>P<\/jats:italic>\u2003=\u20030.003), and calcium\u2010phosphorus product increased from 3.48\u2003\u00b1\u20030.82\u2003mmol<jats:sup>2<\/jats:sup>\/L<jats:sup>2<\/jats:sup> (mean\u2003\u00b1\u2003SD) in stage 1 to 3.76\u2003\u00b1\u20031.00\u2003mmol<jats:sup>2<\/jats:sup>\/L<jats:sup>2<\/jats:sup> in stage 2 (<jats:italic>P<\/jats:italic>\u2003=\u20030.017), they remained in the target levels recommended by the Kidney Disease Outcomes Quality Initiative guidelines. No serious effects were observed during stage 1 and stage 2, respectively. Intravenous alfacalcidol once weekly is effective, safe and less costly in suppressing intact parathyroid hormone compared to twice or thrice weekly administration in chronic hemodialysis patients.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2012.01131.x","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T11:31:25Z","timestamp":1351596685000},"page":"30-34","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous Alfacalcidol Once Versus Twice or Thrice Weekly in Hemodialysis Patients"],"prefix":"10.1111","volume":"17","author":[{"given":"Abdulrazak","family":"Alghareeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Bawadekji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alsaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188732"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92197-1"},{"key":"e_1_2_6_5_2","first-page":"566","article-title":"Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure","volume":"19","author":"Cozzolino M","year":"2006","journal-title":"J Nephrol"},{"issue":"3","key":"e_1_2_6_6_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90459-5"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080087"},{"issue":"3","key":"e_1_2_6_9_2","first-page":"S16","article-title":"National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults","volume":"47","author":"K\/DOQI","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00240.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.9.1553"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28108"},{"issue":"41","key":"e_1_2_6_13_2","first-page":"S121","article-title":"Improvement of severe secondary hyperparathyroidism in dialysis patient by intravenous 1alpha(OH) vitamin D3, oral Ca CO3 and low dialysate calcium","volume":"43","author":"Moriniere P","year":"1993","journal-title":"Kidney Int"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004070573"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg513"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.12.2907"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000133973.86816.e9"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(97)90212-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg414"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001542"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00559.x"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2012.01131.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2012.01131.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:41:36Z","timestamp":1697254896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2012.01131.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1744-9987.2012.01131.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2012.01131.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,30]]}}}